Research Article
[Retracted] Identification of Gene-Tyrosine Kinase 2 (TYK2) in Head and Neck Squamous Cell Carcinoma Patients—An Integrated Bioinformatics Approach
Table 1
Association between MMP14 expression and clinicopathologic features in TCGA-HNSC cohort.
| | Characteristic | Low expression of TYK2 | High expression of TYK2 | | Statistic | Method |
| | 251 | 251 | | | | | T stage, (%) | | | 0.273 | 3.89 | Chi square test | | T1 | 19 (3.9%) | 14 (2.9%) | | | | | T2 | 66 (13.6%) | 78 (16%) | | | | | T3 | 72 (14.8%) | 59 (12.1%) | | | | | T4 | 83 (17%) | 96 (19.7%) | | | | | N stage, (%) | | | 0.007 | | Fisher’s test | | N0 | 121 (25.2%) | 118 (24.6%) | | | | | N1 | 50 (10.4%) | 30 (6.2%) | | | | | N2 | 61 (12.7%) | 93 (19.4%) | | | | | N3 | 3 (0.6%) | 4 (0.8%) | | | | | M stage, (%) | | | 0.029 | | Fisher’s test | | M0 | 231 (48.4%) | 241 (50.5%) | | | | | M1 | 5 (1%) | 0 (0%) | | | | | Clinical stage, (%) | | | 0.093 | 6.41 | Chi square test | | Stage I | 13 (2.7%) | 6 (1.2%) | | | | | Stage II | 49 (10%) | 46 (9.4%) | | | | | Stage III | 56 (11.5%) | 46 (9.4%) | | | | | Stage IV | 122 (25%) | 150 (30.7%) | | | | | Radiation therapy, (%) | | | 0.158 | 2 | Chi square test | | No | 83 (18.8%) | 71 (16.1%) | | | | | Yes | 133 (30.2%) | 154 (34.9%) | | | | | Primary therapy outcome, (%) | | | 0.110 | | Fisher’s test | | PD | 27 (6.5%) | 14 (3.3%) | | | | | SD | 3 (0.7%) | 3 (0.7%) | | | | | PR | 3 (0.7%) | 3 (0.7%) | | | | | CR | 168 (40.2%) | 197 (47.1%) | | | | | Gender, (%) | | | 0.012 | 6.36 | Chi square test | | Female | 80 (15.9%) | 54 (10.8%) | | | | | Male | 171 (34.1%) | 197 (39.2%) | | | | | Race, (%) | | | 0.166 | | Fisher’s test | | Asian | 8 (1.6%) | 2 (0.4%) | | | | | Black or African American | 22 (4.5%) | 25 (5.2%) | | | | | White | 214 (44.1%) | 214 (44.1%) | | | | | Age, (%) | | | 0.044 | 4.04 | Chi square test | | ≤60 | 111 (22.2%) | 134 (26.7%) | | | | | >60 | 140 (27.9%) | 116 (23.2%) | | | | | Histologic grade, (%) | | | <0.001 | | Fisher’s test | | G1 | 49 (10.1%) | 13 (2.7%) | | | | | G2 | 159 (32.9%) | 141 (29.2%) | | | | | G3 | 38 (7.9%) | 81 (16.8%) | | | | | G4 | 0 (0%) | 2 (0.4%) | | | | | Anatomic neoplasm subdivision, (%) | | | <0.001 | 36.1 | Chi square test | | Alveolar ridge | 11 (2.2%) | 7 (1.4%) | | | | | Base of tongue | 7 (1.4%) | 16 (3.2%) | | | | | Buccal mucosa | 14 (2.8%) | 8 (1.6%) | | | | | Floor of mouth | 33 (6.6%) | 28 (5.6%) | | | | | Hard palate | 4 (0.8%) | 3 (0.6%) | | | | | Hypopharynx | 3 (0.6%) | 7 (1.4%) | | | | | Larynx | 48 (9.6%) | 63 (12.5%) | | | | | Lip | 1 (0.2%) | 2 (0.4%) | | | | | Oral cavity | 41 (8.2%) | 31 (6.2%) | | | | | Oral tongue | 78 (15.5%) | 48 (9.6%) | | | | | Oropharynx | 4 (0.8%) | 5 (1%) | | | | | Tonsil | 7 (1.4%) | 33 (6.6%) | | | | | Alcohol history, (%) | | | 0.071 | 3.26 | Chi square test | | No | 89 (18.1%) | 69 (14.1%) | | | | | Yes | 157 (32%) | 176 (35.8%) | | | | | Smoker, (%) | | | 0.829 | 0.05 | Chi square test | | No | 54 (11%) | 57 (11.6%) | | | | | Yes | 192 (39%) | 189 (38.4%) | | | | | Lymphovascular invasion, (%) | | | 0.534 | 0.39 | Chi square test | | No | 115 (33.7%) | 104 (30.5%) | | | | | Yes | 59 (17.3%) | 63 (18.5%) | | | | | Lymph node neck dissection, (%) | | | 0.891 | 0.02 | Chi square test | | No | 44 (8.8%) | 46 (9.2%) | | | | | Yes | 206 (41.3%) | 203 (40.7%) | | | | | OS event, (%) | | | 0.038 | 4.29 | Chi square test | | Alive | 130 (25.9%) | 154 (30.7%) | | | | | Dead | 121 (24.1%) | 97 (19.3%) | | | | | PFI event, (%) | | | 0.082 | 3.03 | Chi square test | | Alive | 144 (28.7%) | 164 (32.7%) | | | | | Dead | 107 (21.3%) | 87 (17.3%) | | | | | DSS event, (%) | | | 0.032 | 4.62 | Chi square test | | Alive | 160 (33.5%) | 187 (39.2%) | | | | | Dead | 75 (15.7%) | 55 (11.5%) | | | | | Age, median (IQR) | 62 (53.5, 70) | 60 (53, 67) | 0.049 | 34561 | Wilcoxon |
|
|
